Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as VIMOVO (AstraZeneca)
VIMOVO · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Treatment order : A, B, C |
| 2 | EXPERIMENTAL | Treatment order : B, C, A |
| 3 | EXPERIMENTAL | Treatment order : C, A, B |
| 4 | EXPERIMENTAL | Treatment order : A, C, B |
| 5 | EXPERIMENTAL | Treatment order : B, A, C |
| 6 | EXPERIMENTAL | Treatment order : C, B, A |
| Name | Type | Description |
|---|---|---|
| VIMOVO (AstraZeneca) | DRUG | VIMOVO (AstraZeneca) 500 mg naproxen/20 mg esomeprazole |
| VIMOVO (Patheon) | DRUG | VIMOVO (Patheon) 500 mg naproxen/20 mg esomeprazole |
| Marketed enteric-coated naproxen formulation | DRUG | Marketed enteric-coated naproxen formulation (manufactured by Roche) 500 mg tablet |
Inclusion Criteria: * Healthy male or female volunteer, aged 18 - 55 years (inclusive) * Female volunteers must be non-pregnant and non-lactating and have a negative urine pregnancy test result prior to enrolment into the study. * Female volunteers of childbearing potential must be using appropriat...
VIMOVO is a small molecule medicine developed by AstraZeneca PLC. It has been studied in a Phase 1 bioequivalence trial in healthy adult volunteers in the United Kingdom. The specific therapeutic indication for VIMOVO is not publicly disclosed in the available development information.
VIMOVO is made and developed by AstraZeneca PLC, which trades under the ticker AZN. The drug has been manufactured at AstraZeneca AB as well as by Patheon Pharmaceuticals, and it has also been compared with a marketed enteric-coated naproxen formulation.
VIMOVO is in Phase 1 clinical development. One Phase 1 trial has been completed, and no trials are currently active. The completed study was a bioequivalence study, not an efficacy trial, and it enrolled 36 healthy volunteers.
VIMOVO has been studied in one completed Phase 1 trial, NCT01331993. That trial was a bioequivalence study comparing VIMOVO manufactured at AstraZeneca AB with VIMOVO manufactured by Patheon Pharmaceuticals and with a marketed enteric-coated naproxen formulation. It enrolled 36 healthy volunteers in the United Kingdom.
Yes. VIMOVO is also referred to as VIMOVO (AstraZeneca). Both names refer to the same small molecule asset developed by AstraZeneca PLC, ticker AZN, so searches using either name point to the same drug program.
The VIMOVO bioequivalence trial, NCT01331993, was a completed Phase 1 study with 36 enrolled healthy volunteers in the United Kingdom. It was randomized and controlled but not double blind, and it included adults aged 18 years and older of all sexes.